SLC18A2 and Parkinson disease: Using a novel 18F-tetrabenazine derivative [18F-FP-(+)-DTBZ or 18F-AV-133], Okamura et al. detected the greatest regional decrease in VMAT2 binding in the posterior putamen, followed by anterior putamen and caudate nucleus in PD [147].